Her rheumatologist instructed her to undergo a baseline ocular examination prior to initiating Plaquenil (hydroxychloroquine, Sanofi-Aventis) therapy. Toxic maculopathy associated with chloroquine use was first documented in the literature five decades ago.1 In the United States, Plaquenil––an analog to chloroquine––is used to treat a variety of conditions, including rheumatoid arthritis, lupus and several distinct inflammatory disorders. Although the incidence of macular toxicity is infrequent with Plaquenil use (at a dosage of 200mg or 400mg q.d.), its visual impact can be devastating. Hydroxychloroquine lupus panniculitis Teaching about hydroxychloroquine ati testing Retinal toxicity is irreversible and can progress after cessation of hydroxychloroquine, thus early screening is important to limit potential vision loss. Baseline screening and annual screening after five years is recommended. Background. The American Academy of Ophthalmology recommendations for screening of chloroquine CQ and hydroxychloroquine HCQ retinopathy were published in 2002, but improved screening tools and new knowledge about the prevalence of toxicity have appeared in the ensuing years. The Royal College of Ophthalmologists - Hydroxychloroquine and Ocular Toxicity Recommendations on Screening – October 2009 Dubois EL, Tuffanelli DL Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA. 1964;14-111. Initially, central visual acuity may be unaffected, but the patient may notice related paracentral scotomas that often interfere with reading. The associated classic retinal toxicity is described as a bull’s eye maculopathy (ring of depigmented retinal pigment epithelium that spares the foveal area). Hydroxychloroquine and ocular toxicity recommendations on screening 2009 Hydroxychloroquine use the potential impact of new ocular., Revised Recommendations on Screening for Chloroquine and. Plaquenil eval icd 10Chloroquine ph 500 mg tabletPlaquenil and hpv Tehrani R, Ostrowski RA, Hariman R, Jay WM Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008, 233201-209. Marmor MF, Kellner U, Lai TY, Lyons JS, Melles RB, Mieler WF Recommendations on screening for chloroquine and hydroxychloroquine retinopathy 2016 Revision. Ophthalmology 2016, 186-1394. Hydroxychloroquine Plaquenil Toxicity and.. Hydroxchloroquine and Chloroquine Toxicity. My Take on New Ocular Screening Guidelines for Plaquenil.. Hydroxychloroquine and ocular toxicity recommendations on screening October 2009. HIR36837 Publisher Royal College of. Diseases 2 Chemicals 1 Aims This guideline considers the avoidance of optical damage when using the drug hydroxychloroquine, which is also used to treat rheumatoid arthritis and lupus. Intended audience. The Royal College of Ophthalmologists—Hydroxychloroquine and Ocular Toxicity. Recommendations on Screening, October 2009. 9. Frederick W, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Screening recommendation. Guidelines and recommendations for screening for retinal toxicity have evolved over the years. In 2002 the American Academy of Ophthalmology AAO first proposed screening recommendations for HCQ associated retinal toxicity, with the salient points being 14 1.